Objective To discuss the curative effect and influence on intestinal neurotransmitters of Clostridium butyricum powder combined with lactulose on children with functional constipation ( FC) .Methods Ninety-two cases of children with FC were divided into experimental group and control group randomly with 46 cases in both groups .Two groups were given basic medical treatment , including plenty of water , adjustment of unhealthy eating habit , training stool habit and suitable activities .Children in the experimental group were additionally given oral Clostridium butyricum powder (0.5g per time, twice a day with warm boiled water ) and Lactulose oral liquid (5ml per time, twice a day taken orally ) , while children in the control group were given Lactulose oral liquid with same method and dose for 6 weeks .The changes of constipation symptom score and stool classification of children in two groups were recorded , and the clinical curative effects were evaluated as well .The changes of serum nitric oxide ( NO ) and vasoactive intestinal peptide ( VIP ) levels before and after medical treatment were detected .Results After 6 weeks ’ medical treatment , constipation symptom score of children in two groups declined obviously than before (t value was 2.97 and 2.16, respectively, both P<0.05), while stool classification rose obviously than before (t value was 3.67 and 2.42, respectively, both P<0.05).The declining or rising degree of children in the experimental group were much greater than those in the control group (t value was 2.18 and 2.43, respectively, both P<0.05).Meanwhile, the total clinical efficiency of the experimental group was much higher than the control group (χ2 =5.06,P<0.05).There were 5 and 3 cases with adverse reactions in the experimental group (10.87%) and the control group (6.52%), respectively with light symptoms, and no statistical differences appeared between two groups (χ2 =0.14, P>0.05).After 6 weeks’ medical treatment, serum NO and VIP levels of children in two groups declined obviously than before (t value was 2.89 and 3.27, respectively in the experimental group , both P<0.05;t value was 2.19 and 2.39, respectively in the control group , both P<0.05), and the declining degree of the experimental group was much greater than the control group (t value was 2.21 and 2.32, respectively, both P <0.05).Conclusion Clostridium butyricum powder combined with Lactulose has significant clinical effect on children with FC .It can improve stool classification obviously , reduce constipation symptom score, reduce serum NO and VIP levels , and improve intestinal motility with favorable security .%目的：探讨酪酸梭菌活菌散联合乳果糖对小儿功能性便秘（ FC）的疗效。方法将92例儿童FC患儿随机分为实验组和对照组各46例。两组患儿均予以多饮水、纠正不良饮食习惯、训练排便习惯和进行适量活动等基础治疗。实验组患儿加用口服酪酸梭菌活菌散（0．5g／次，2次／d，温水冲服）联合乳果糖口服液（5mL／次，2次／d，口服）治疗；对照组患儿予以相同用法及剂量的乳果糖口服液治疗，均连用6周。记录两组患儿治疗前后便秘症状评分和粪便性状分级的变化，并评估其临床效果，并检测治疗前后血清一氧化氮（ NO）和血管活性肠肽（ VIP）水平的变化。结果治疗6周后，实验组和对照组患儿便秘症状评分均较治疗前明显下降（t值分别为2．97、2．16，均P＜0．05），粪便性状分级均较治疗前明显上升（t值分别为3．67、2．42，均P＜0．05），且实验组便秘症状评分、粪便性状分级的变化幅度明显大于对照组（t值分别为2．18、2．43，均P＜0．05）；总有效率实验组患儿明显高于对照组（χ2＝5．06，P＜0．05）。实验组和对照组治疗中分别出现不良反应5例（10．87％）和3例（6．52％），症状均较轻，两组患儿不良反应发生率比较差异无统计学意义（χ2＝0．14，P＞0．05）；治疗6周后，两组患儿血清NO和VIP水平均较治疗前明显下降（实验组：t值分别为2．89、3．27，均P＜0．05；对照组t值分别为2．19、2．39；均P＜0．05），且实验组下降程度较对照组更明显（t值分别为2．21、2．32，均P＜0．05）。结论口服酪酸梭菌活菌散联合乳果糖治疗儿童FC的临床效果较显著，能明显改善其粪便性状，降低便秘症状评分，降低血清NO和VIP水平，改善肠动力障碍，且安全性亦较好。
展开▼
